Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug candidate, PLAT001. This novel injectable drug is under evaluation for the treatment of general advanced or metastatic solid tumors.
PLAT001, classified as a new nanomedicine, is a polymer-coupled small molecule drug designed to target advanced or metastatic solid tumors. Preclinical efficacy studies have demonstrated that PLAT001 exerts a significant tumor inhibitory effect in various animal models, including those for pancreatic and liver cancers. This latest approval follows an earlier clinical trial green light for PLAT001 in the United States, which Poly Pharm received in December of the previous year.- Flcube.com
